Cancer Prevention Pharmaceuticals, Inc. (CPP), a private biotech company developing novel therapeutics to prevent cancer and other diseases, announced today that the U.S. Food and Drug Administration (FDA) has granted “Fast-Track” status for its lead drug CPP-1X/sul for adults with familial adenomatous polyposis (FAP), which is currently in a Phase 3 clinical trial. FAP is a rare genetic disease that if left untreated progresses to colorectal cancer in nearly 100% of patients. Currently there is no effective treatment for FAP.
{iframe}http://www.businesswire.com/news/home/20170918005178/en/FDA-Grants-%E2%80%9CFast-Track%E2%80%9D-Status-Cancer-Prevention{/iframe}